Omeros Corp Stock in 2019 Q1 Driven by Institutional Investors

Omeros Corporation (NASDAQ:OMER) Logo

Sentiment for Omeros Corp (NASDAQ:OMER)

Omeros Corp (NASDAQ:OMER) institutional sentiment decreased to 1 in Q1 2019. Its down -0.51, from 1.51 in 2018Q4. The ratio dived, as 42 hedge funds started new or increased equity positions, while 42 reduced and sold holdings in Omeros Corp. The hedge funds in our partner’s database now have: 24.17 million shares, up from 22.48 million shares in 2018Q4. Also, the number of hedge funds holding Omeros Corp in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 13 Reduced: 29 Increased: 28 New Position: 14.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $892.80 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

The stock decreased 2.03% or $0.37 during the last trading session, reaching $17.83. About 373,189 shares traded. Omeros Corporation (NASDAQ:OMER) has declined 24.60% since September 10, 2018 and is downtrending. It has underperformed by 24.60% the S&P500.

Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on November, 14. They expect $-0.38 EPS, up 46.48 % or $0.33 from last year’s $-0.71 per share. After $-0.29 actual EPS reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 31.03 % negative EPS growth.

Ingalls & Snyder Llc holds 4.2% of its portfolio in Omeros Corporation for 5.08 million shares. Consonance Capital Management Lp owns 2.12 million shares or 2.33% of their US portfolio. Moreover, Rocky Mountain Advisers Llc has 0.94% invested in the company for 15,210 shares. The Massachusetts-based Capital Impact Advisors Llc has invested 0.7% in the stock. American Financial Group Inc, a Ohio-based fund reported 340,284 shares.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Ratings analysis reveals 50% of Omeros Corp’s analysts are positive. Out of 2 Wall Street analysts rating Omeros Corp, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $17 while the high is $2600. The stock’s average target of $21.50 is 20.58% above today’s ($17.83) share price. OMER was included in 2 notes of analysts from March 12, 2019. On Tuesday, March 12 the stock rating was maintained by Wedbush with “Hold”.

More notable recent Omeros Corporation (NASDAQ:OMER) news were published by: Nasdaq.com which released: “Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know – Nasdaq” on August 01, 2019, also Nasdaq.com with their article: “Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates – Nasdaq” published on August 08, 2019, Nasdaq.com published: “Spreadshirt expands partnership with Kornit Digital to support growth – Nasdaq” on September 03, 2019. More interesting news about Omeros Corporation (NASDAQ:OMER) were released by: Nasdaq.com and their article: “Notable Wednesday Option Activity: DOV, WCG, OMER – Nasdaq” published on April 17, 2019 as well as Finance.Yahoo.com‘s news article titled: “Omeros (OMER) Q2 2019 Earnings Call Transcript – Yahoo Finance” with publication date: August 09, 2019.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.